Denosumab  	Denosumab  	 NNP	B-NP
-  	-  	 :	O
a  	a  	 DT	O
new  	new  	 JJ	O
option  	option  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
osteoporosis  	osteoporosis  	 JJ	B-NP
Denosumab  	Denosumab  	 NNP	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
international  	international  	 JJ	O
name  	name  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
human 	human 	 JJ	O
,  	,  	 ,	O
monoclonal  	monoclonal  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
approved  	approved  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
osteoporosis 	osteoporosis 	 NN	B-NP
.  	.  	 .	O
This  	This  	 DT	O
antibody  	antibody  	 NN	B-NP
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
RANK  	RANK  	 NNP	B-NP
ligand  	ligand  	 NNS	I-NP
( 	( 	 -LRB-	O
RANKL 	RANKL 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
inactivating  	inactivating  	 VBD	O
it 	it 	 PRP	O
.  	.  	 .	O
In  	In  	 IN	O
consequence 	consequence 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
formation  	formation  	 NN	O
and  	and  	 CC	O
survival  	survival  	 NN	O
of  	of  	 IN	O
osteoclasts  	osteoclasts  	 NNS	B-NP
are  	are  	 VBP	O
suppressed 	suppressed 	 VBN	O
,  	,  	 ,	O
leading  	leading  	 VBG	O
to  	to  	 TO	O
their  	their  	 PRP$	O
apoptosis 	apoptosis 	 NN	B-NP
.  	.  	 .	O
All  	All  	 PDT	O
this  	this  	 DT	O
results  	results  	 NNS	O
in  	in  	 IN	O
lower  	lower  	 JJR	O
bone  	bone  	 NN	B-NP
resorption 	resorption 	 NN	I-NP
,  	,  	 ,	O
while  	while  	 IN	O
bone  	bone  	 NN	B-NP
mineral  	mineral  	 NN	I-NP
density  	density  	 NNS	I-NP
( 	( 	 -LRB-	O
BMD 	BMD 	 NNP	B-NP
)  	)  	 -RRB-	O
increases 	increases 	 NNS	O
.  	.  	 .	O
Denosumab  	Denosumab  	 NNP	B-NP
also  	also  	 RB	O
reduces  	reduces  	 VBZ	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
vertebral  	vertebral  	 NN	B-NP
and  	and  	 CC	O
non-vertebral  	non-vertebral  	 JJ	B-NP
fractures 	fractures 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
agent  	agent  	 NN	B-NP
is  	is  	 VBZ	O
similarly  	similarly  	 RB	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
various  	various  	 JJ	O
stages  	stages  	 NNS	O
of  	of  	 IN	O
renal  	renal  	 JJ	B-NP
function  	function  	 NN	I-NP
impairment 	impairment 	 NNS	I-NP
;  	;  	 :	O
it  	it  	 PRP	O
does  	does  	 VBZ	O
not  	not  	 RB	O
impair  	impair  	 VB	O
fracture  	fracture  	 JJ	B-NP
healing  	healing  	 NN	I-NP
processes  	processes  	 NNS	I-NP
nor  	nor  	 CC	O
contribute  	contribute  	 VB	O
to  	to  	 TO	O
atherosclerosis  	atherosclerosis  	 VB	O
progression  	progression  	 VBN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
high  	high  	 JJ	O
cardiovascular  	cardiovascular  	 JJ	B-NP
risks 	risks 	 NNS	I-NP
.  	.  	 .	O
Following  	Following  	 VBG	O
an  	an  	 DT	O
analysis  	analysis  	 NN	O
of  	of  	 IN	O
adverse  	adverse  	 JJ	O
effects 	effects 	 NNS	O
,  	,  	 ,	O
performed  	performed  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
FREEDOM  	FREEDOM  	 NNP	B-NP
study  	study  	 NN	I-NP
( 	( 	 -LRB-	O
in  	in  	 IN	O
which  	which  	 WDT	O
it  	it  	 PRP	O
was  	was  	 VBD	O
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
majority  	majority  	 NN	O
of  	of  	 IN	O
adverse  	adverse  	 JJ	O
effects  	effects  	 NNS	O
observed  	observed  	 VBD	O
in  	in  	 IN	O
the  	the  	 DT	O
course  	course  	 NN	O
of  	of  	 IN	O
denosumab  	denosumab  	 JJ	B-NP
use  	use  	 NN	I-NP
was  	was  	 VBD	O
similar  	similar  	 JJ	O
to  	to  	 TO	O
that  	that  	 DT	O
in  	in  	 IN	O
the  	the  	 DT	O
placebo  	placebo  	 JJ	O
group 	group 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
its  	its  	 PRP$	O
safety  	safety  	 NN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
can  	can  	 MD	O
definitely  	definitely  	 RB	O
be  	be  	 VB	O
confirmed 	confirmed 	 VBN	O
.  	.  	 .	O
